Novo Bets On ‘Chequered’ CB1r Approach In Diabetic Kidney Disease With Inversago Buy
For Up To $1.08bn
The Danish firm’s Q2 sales fell short of expectations due to poor rare disease and diabetes performance, but a potentially billion-dollar buy of Inversago stole attention as observers highlighted the historical risks of targeting the cannabinoid-1 receptor.
You may also be interested in...
Despite the astounding efficacy and commercial potential of incretins in obesity, many groups are trying different mechanistic approaches to the disease – if only to enable combinations.
Bristol and Regeneron sign separate cell therapy technology pacts, plus deals involving Takeda/ImmunoGen, Serina/AgeX, Cybin/Small Pharma, Taiho/Phost’in, Royalty/Ferring and Aardvark/GRI Bio.
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.